Interferon-γ resets muscle cell fate by stimulating the sequential recruitment of JARID2 and PRC2 to promoters to repress myogenesis

Science Signaling

Volumn 6, Issue 305, 2013, Pages

  Londhe, Priya ^a   Davie, Judith K ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HISTONE H3; JUMONJI FAMILY PROTEIN; MYOGENIN; POLYCOMB REPRESSIVE COMPLEX 2; RNA POLYMERASE II; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ARTICLE; CELL FATE; CHRONIC INFLAMMATION; GENE REPRESSION; MUSCLE CELL; MUSCLE DEVELOPMENT; PRIORITY JOURNAL; PROMOTER REGION;

ANIMALS; BLOTTING, WESTERN; CELL LINE; GENE EXPRESSION; HEK293 CELLS; HISTONES; HUMANS; INTERFERON-GAMMA; METHYLATION; MUSCLE DEVELOPMENT; MYOBLASTS; MYOGENIN; NUCLEAR PROTEINS; PHOSPHORYLATION; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA POLYMERASE II; SERINE; TRANS-ACTIVATORS;

EID: 84891845285     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004633     Document Type: Article

References (62)

1. M. H. Parker, P. Seale, M. A. Rudnicki, Looking back to the embryo: Defining transcriptional networks in adult myogenesis. Nat. Rev. Genet. 4, 497-507 (2003).
2. P. Hasty, A. Bradley, J. H. Morris, D. G. Edmondson, J. M. Venuti, E. N. Olson, W. H. Klein, Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. Nature 364, 501-506 (1993).
3. Y. Nabeshima, K. Hanaoka, M. Hayasaka, E. Esumi, S. Li, I. Nonaka, Y. Nabeshima, Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature 364, 532-535 (1993).
4. S. B. Chargé, M. A. Rudnicki, Cellular and molecular regulation of muscle regeneration. Physiol. Rev. 84, 209-238 (2004).
5. M. Cheng, M. H. Nguyen, G. Fantuzzi, T. J. Koh, Endogenous interferon-γ is required for efficient skeletalmuscle regeneration. Am. J. Physiol. Cell Physiol. 294, C1183-C1191 (2008).
6. E. A. Bach, M. Aguet, R. D. Schreiber, The IFNγ receptor: A paradigm for cytokine receptor signaling. Ann. Rev. Immunol. 15, 563-591 (1997).
7. M. Munder, M. Mallo, K. Eichmann, M. Modolell, Direct stimulation of macrophages by IL-12 and IL-18 - A bridge built on solid ground. Immunol. Lett. 75, 159-160 (2001).
8. T. Fukao, S. Matsuda, S. Koyasu, Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-γ production by dendritic cells. J. Immunol. 164, 64-71 (2000).
9. U. Boehm, T. Klamp, M. Groot, J. C. Howard, Cellular responses to interferon-γ. Annu. Rev. Immunol. 15, 749-795 (1997).
10. W. Foster, Y. Li, A. Usas, G. Somogyi, J. Huard, Gamma interferon as an antifibrosis agent in skeletal muscle. J. Orthop. Res. 21, 798-804 (2003).
11. G. D. Shelton, N. A. Calcutt, R. S. Garrett, D. Gu, N. Sarvetnick, W. M. Campana, H. C. Powell, Necrotizing myopathy induced by overexpression of interferon-γ in transgenic mice. Muscle Nerve 22, 156 -165 (1999).
12. S. A. Villalta, B. Deng, C. Rinaldi, M. Wehling-Henricks, J. G. Tidball, IFN-γ promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation. J. Immunol. 187, 5419 - 5428 (2011).
13. J. Lagrota-Candido, R. Vasconcellos, M. Cavalcanti, M. Bozza, W. Savino, T. Quirico-Santos, Resolution of skeletal muscle inflammation in mdx dystrophic mouse is accompanied by increased immunoglobulin and interferon-γ production. Int. J. Exp. Pathol. 83, 121-132 (2002).
14. J. P. Ting, K. L.Williams, The CATERPILLER family: An ancient family of immune/apoptotic proteins. Clin. Immunol. 115, 33-37 (2005).
15. Z. Ye, J. P. Ting, NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr. Opin. Immunol. 20, 3-9 (2008).
16. C. Griscelli, B. Lisowska-Grospierre, B. Mach, Combined immunodeficiency with defective expression in MHC class II genes. Immunodefic. Rev. 1, 135- 153 (1989).
17. A. DeSandro, U. M. Nagarajan, J. M. Boss, The bare lymphocyte syndrome: Molecular clues to the transcriptional regulation of major histocompatibility complex class II genes. Am. J. Hum. Genet. 65, 279-286 (1999).
18. J. M.Waldburger, K. Masternak, A. Muhlethaler-Mottet, J. Villard, M. Peretti, S. Landmann, W. Reith, Lessons from the bare lymphocyte syndrome: Molecular mechanisms regulating MHC class II expression. Immunol. Rev. 178, 148-165 (2000).
19. A. M. DeSandro, U. M. Nagarajan, J. M. Boss, Associations and interactions between bare lymphocyte syndrome factors. Mol. Cell. Biol. 20, 6587-6599 (2000).
20. K. Masternak, A. Muhlethaler-Mottet, J. Villard, M. Zufferey, V. Steimle, W. Reith, CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 14, 1156-1166 (2000).
21. T. Scholl, S. K. Mahanta, J. L. Strominger, Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Proc. Natl. Acad. Sci. U.S.A. 94, 6330-6334 (1997).
22. X. S. Zhu, M. W. Linhoff, G. Li, K. C. Chin, S. N. Maity, J. P. Ting, Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol. Cell. Biol. 20, 6051-6061 (2000).
23. V. Steimle, L. A. Otten, M. Zufferey, B. Mach, Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75, 135-146 (1993).
24. J. A. Gomez, P. Majumder, U. M. Nagarajan, J. M. Boss, X box-like sequences in the MHC class II region maintain regulatory function. J. Immunol. 175, 1030- 1040 (2005).
25. N. Rybtsova, E. Leimgruber, Q. Seguin-Estévez, I. Dunand-Sauthier, M. Krawczyk, W. Reith, Transcription-coupled deposition of histone modifications during MHC class II gene activation. Nucleic Acids Res. 35, 3431-3441 (2007).
26. J. Müller, C. M. Hart, N. J. Francis, M. L. Vargas, A. Sengupta, B. Wild, E. L. Miller, M. B. O' Connor, R. E. Kingston, J. A. Simon, Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 111, 197 -208 (2002).
27. R. Cao, L. Wang, H. Wang, L. Xia, H. Erdjument-Bromage, P. Tempst, R. S. Jones, Y. Zhang, Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039 -1043 (2002).
28. A. Kuzmichev, K. Nishioka, H. Erdjument-Bromage, P. Tempst, D. Reinberg, Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16, 2893-2905 (2002).
29. M. L. Conerly, K. L. MacQuarrie, A. P. Fong, Z. Yao, S. J. Tapscott, Polycomb-mediated repression during terminal differentiation: What don't you want to be when you grow up? Genes Dev. 25, 997-1003 (2011).
30. F. Relaix, D. Rocancourt, A. Mansouri, M. Buckingham, A Pax3/Pax7-dependent population of skeletal muscle progenitor cells. Nature 435, 948-953 (2005).
31. A. H. Juan, A. Derfoul, X. Feng, J. G. Ryall, S. Dell'Orso, A. Pasut, H. Zare, J. M. Simone, M. A. Rudnicki, V. Sartorelli, Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells. Genes Dev. 25, 789-794 (2011).
32. G. Caretti, M. Di Padova, B. Micales, G. E. Lyons, V. Sartorelli, The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev. 18, 2627-2638 (2004).
33. G. Li, R. Margueron, M. Ku, P. Chambon, B. E. Bernstein, D. Reinberg, Jarid2 and PRC2, partners in regulating gene expression. Genes Dev. 24, 368- 380 (2010).
34. D. Landeira, S. Sauer, R. Poot, M. Dvorkina, L. Mazzarella, H. F. Jørgensen, C. F. Pereira, M. Leleu, F. M. Piccolo, M. Spivakov, E. Brookes, A. Pombo, C. Fisher, W. C. Skarnes, T. Snoek, K. Bezstarosti, J. Demmers, R. J. Klose, M. Casanova, L. Tavares, N. Brockdorff, M. Merkenschlager, A. G. Fisher, Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA polymerase II to developmental regulators. Nat. Cell Biol. 12, 618-624 (2010).
35. P. Londhe, J. K. Davie, Gamma interferon modulates myogenesis through the major histocompatibility complex class II transactivator, CIITA. Mol. Cell. Biol. 31, 2854-2866 (2011).
36. S. Buratowski, Progression through the RNA polymerase II CTD cycle. Mol. Cell 36, 541-546 (2009).
37. S. Kanazawa, T. Okamoto, B. M. Peterlin, Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 12, 61-70 (2000).
38. R. Mudhasani, J. D. Fontes, Inhibition of class II trans-activator function by HIV-1 tat in mouse cells is independent of competition for binding to cyclin T1. Mol. Immunol. 38, 539-546 (2002).
39. G. A. Hartzog, T. Wada, H. Handa, F. Winston, Evidence that Spt4, Spt5, and Spt6 control transcription elongation by RNA polymerase II in Saccharomyces cerevisiae. Genes Dev. 12, 357-369 (1998).
40. T. Wada, T. Takagi, Y. Yamaguchi, A. Ferdous, T. Imai, S. Hirose, S. Sugimoto, K. Yano, G. A. Hartzog, F. Winston, S. Buratowski, H. Handa, DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs. Genes Dev. 12, 343-356 (1998).
41. P. Asp, R. Blum, V. Vethantham, F. Parisi, M. Micsinai, J. Cheng, C. Bowman, Y. Kluger, B. D. Dynlacht, Genome-wide remodeling of the epigenetic landscape during myogenic differentiation. Proc. Natl. Acad. Sci. U.S.A. 108, E149-E158 (2011).
42. C. Martin, Y. Zhang, The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6, 838-849 (2005).
43. B. E. Bernstein, M. Kamal, K. Lindblad-Toh, S. Bekiranov, D. K. Bailey, D. J. Huebert, S. McMahon, E. K. Karlsson, E. J. Kulbokas III, T. R. Gingeras, S. L. Schreiber, E. S. Lander, Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120, 169-181 (2005).
44. R. Schneider, A. J. Bannister, F. A. Myers, A.W. Thorne, C. Crane-Robinson, T. Kouzarides, Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat. Cell Biol. 6, 73-77 (2004).
45. P. Londhe, J. K. Davie, Sequential association of myogenic regulatory factors and E proteins at muscle-specific genes. Skelet. Muscle 1, 14 (2011).
46. A. J. Bannister, P. Zegerman, J. F. Partridge, E. A. Miska, J. O. Thomas, R. C. Allshire, T. Kouzarides, Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410, 120-124 (2001).
47. S. Acharyya, S. M. Sharma, A. S. Cheng, K. J. Ladner, W. He, W. Kline, H. Wang, M. C. Ostrowski, T. H. Huang, D. C. Guttridge, TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: Implications in duchenne muscular dystrophy. PLOS One 5, e12479 (2010).
48. T. Margaritis, F. C. Holstege, Poised RNA polymerase II gives pause for thought. Cell 133, 581-584 (2008).
49. P. Gariglio, M. Bellard, P. Chambon, Clustering of RNA polymerase B molecules in the 5′ moiety of the adult b-globin gene of hen erythrocytes. Nucleic Acids Res. 9, 2589-2598 (1981).
50. L. J. Core, J. T. Lis, Transcription regulation through promoter-proximal pausing of RNA polymerase II. Science 319, 1791-1792 (2008).
51. T. H. Kim, L. O. Barrera, M. Zheng, C. Qu, M. A. Singer, T. A. Richmond, Y.Wu, R. D. Green, B. Ren, A high-resolution map of active promoters in the human genome. Nature 436, 876-880 (2005).
52. M. Radonjic, J. C. Andrau, P. Lijnzaad, P. Kemmeren, T. T. Kockelkorn, D. van Leenen, N. L. van Berkum, F. C. Holstege, Genome-wide analyses reveal RNA polymerase II located upstream of genes poised for rapid response upon S. cerevisiae stationary phase exit. Mol. Cell 18, 171-183 (2005).
53. G. W. Muse, D. A. Gilchrist, S. Nechaev, R. Shah, J. S. Parker, S. F.Grissom, J. Zeitlinger, K. Adelman, RNA polymerase is poised for activation across the genome. Nat. Genet. 39, 1507-1511 (2007).
54. D. A. Gilchrist, G. Fromm, G. dos Santos, L. N. Pham, I. E. McDaniel, A. Burkholder, D. C. Fargo, K. Adelman, Regulating the regulators: The pervasive effects of Pol II pausing on stimulus-responsive gene networks. Genes Dev. 26, 933-944 (2012).
55. D. Landeira, A. G. Fisher, Inactive yet indispensable: The tale of Jarid2. Trends Cell Biol. 21, 74-80 (2011).
56. M. R. Mysliwiec, C. D. Carlson, J. Tietjen, H. Hung, A. Z. Ansari, Y. Lee, Jarid2 (Jumonji, AT rich interactive domain 2) regulates NOTCH1 expression via histone modification in the developing heart. J. Biol. Chem. 287, 1235-1241 (2012).
57. R. Margueron, D. Reinberg, The Polycomb complex PRC2 and its mark in life. Nature 469, 343-349 (2011).
58. L. Aloia, B. Di Stefano, L. Di Croce, Polycomb complexes in stem cells and embryonic development. Development 140, 2525-2534 (2013).
59. P. Delgado-Olguín, Y. Huang, X. Li, D. Christodoulou, C. E. Seidman, J. G. Seidman, A. Tarakhovsky, B. G. Bruneau, Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat. Genet. 44, 343- 347 (2012).
60. J. W. Pollard, J. M. Walker, Basic Cell Culture Protocols (Humana Press, Totowa, NJ, ed. 2, 1997).
61. T. A. Rando, H. M. Blau, Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J. Cell Biol. 125, 1275-1287 (1994).
62. P. Komarnitsky, E. J. Cho, S. Buratowski, Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. Genes Dev. 14, 2452-2460 (2000).